Haleon Pakistan Limited (PSX:HALEON)

Market Cap	91.18B +6.6%
Revenue (ttm)	42.67B +8.6%
Net Income	6.55B +24.1%
EPS	55.96 +24.2%
Shares Out	117.05M
PE Ratio	13.92
Forward PE	11.85
Dividend	30.00 (3.85%)
Ex-Dividend Date	Apr 21, 2026

Volume	79,693
Average Volume	80,821
Open	785.00
Previous Close	778.93
Day's Range	758.58 - 794.75
52-Week Range	655.00 - 1,010.00
Beta	0.47
RSI	50.68
Earnings Date	Apr 29, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of pharmaceutical and consumer healthcare products in Pakistan, the Philippines, and Qatar. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company was formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited and changed its name to Haleon Pakistan Limite...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 451
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2025, Haleon Pakistan's revenue was 43.11 billion, an increase of 15.86% compared to the previous year's 37.21 billion. Earnings were 6.37 billion, an increase of 39.21%.